Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Executive Summary

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Advertisement

Related Content

Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine
Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate
Sanofi, Lonza JV Should Offer Pair Flexibility In Biologics Manufacturing
Takeda Extends PRA Alliance To Japan With New JV
Refocus, Optimize, Externalize: Takeda Overhauls Global R&D
Otsuka Looks To New Products As Abilify Plunge Bites

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel